Big Pharma Pacts Benefit From Reduced HBV Biologics Competition
Aligos Candidate Bites The Dust
Partnerships between big pharma and biotech focused on biologic therapies for hepatitis B could reap the benefit of less competition as lone biotechs, such as Aligos, discontinue their candidates.
